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OBJECTIVES: Chronic plantar fasciitis (CPF), the most
common cause of plantar heel pain, lacks an optimal treatment
standard. The electromagnetic Epos® Ultra (EPOS) and the elec-
trohydraulic OssaTron® (OSSA) are the only two FDA approved
extracorporeal shock wave therapy (ESWT) devices for CPF.
This assessment will examine the net health outcomes obtained
when using either of these devices in the treatment of CPF in
patients who failed to achieve satisfactory improvement with
initial conservative treatment. METHODS: Medline® MeSH
heading searches of published peer-reviewed clinical literature
identiﬁed all relevant studies that analyzed ESWT for the treat-
ment of CPF dating to 1996. Additionally, conferences of pro-
fessional organizations were searched for appropriate posters
and abstracts. Outcomes measures focused on the ability of the
comparators to reduce pain and the occurrence of adverse events.
RESULTS: Treatment with EPOS demonstrated pain relief as evi-
denced by visual analog scale (VAS) score improvement from
baseline and compared to control. When compared to control
group, VAS score improvement at 3 months post treatment with
ESWT was signiﬁcantly greater (p = 0.0149). When compared
to baseline VAS scores, the improvement seen at 3, 6, and 12
months post treatment was also signiﬁcantly greater (p < 0.05).
Adverse events in patients using EPOS were limited to pain at
the time of application, which resolved after the treatment was
completed. Treatment with OSSA resulted in greater pain relief
than placebo, revealing an improved VAS score of approximately
1.0 to 2.5 points. Minor adverse events appearing in the area
where the shock wave was applied were resolved within six
weeks. Studies also revealed that ESWT as a whole improved
patients’ mobility scores by 38–51% (p = 0.001) compared to
baseline. CONCLUSIONS: The results of this assessment
demonstrate that both EPOS and OSSA are safe and effective
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OBJECTIVE: Plantar fasciitis (PF), the most common cause of
plantar heel pain, affects middle-aged individuals and comprises
15% of overall foot-related complaints. Initial treatments for 
PF include non-steroidal anti-inﬂammatory drugs (NSAIDs),
custom foot orthotics and/or corticosteroid injections into the
heel. When symptoms persist beyond six months it is classiﬁed
as chronic PF (CPF); two options for treatment, surgical inter-
vention and extracorporeal shock wave therapy (ESWT), exist.
This analysis will determine the cost-effectiveness of ESWT in
relation to surgery for the treatment of CPF. METHODS: A
Markov model was constructed based on established manage-
ment practices for the treatment of CPF, simulating the distrib-
ution of patients into one of ﬁve health and treatment states.
Cost and probability values used to populate the model were
derived from appropriate Medicare reimbursement values, retail
and average wholesale prices and published peer-reviewed clini-
cal studies. Cost and effectiveness values were accumulated
monthly over a 12 month period, yielding incremental cost-
effectiveness ratios (ICERs) in dollars per quality-adjusted life
year ($/QALY). RESULTS: Model analysis reveals that surgery
has a lower overall cost of treatment ($1912 v. $2862 respec-
tively) and a higher overall effectiveness in comparison to ESWT
(0.6742 v. 0.5750 QALY respectively). Surgery dominates ESWT
due to its lower overall cost of treatment and higher effective-
ness value, resulting in a lower ICER as compared to ESWT
($2836/QALY v. $4977/QALY respectively). CONCLUSION:
Based on the results of this analysis, surgery is a more cost-
effective option than ESWT for the treatment of chronic plantar
fasciitis; however, the ICER of each of these methods fall 
below the commonly accepted willingness-to-pay threshold of
$50,000/QALY commonly used by payers for the adoption of
new technology. Therefore when surgery has failed, or is not an
option, ESWT remains a viable and cost-effective alternative.
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OBJECTIVES: The aim of the study is to compare the real hos-
pital cost with DRG reimbursement rate according to surgical
methods in patients with peritrochanteric fractures. METHODS:
Reimbursement data of the Hungarian Diagnosis Related
Groups derive from the ﬁnancial database of the National Health
Insurance Fund Administration. The real hospital costs data
were collected at the Traumatology Center of the University of
Pécs in 2003. We calculated the following cost elements: salaries
of the staff, implants, drugs, bandage, hotel (accommodation)
costs. The salaries and accommodation costs were calculeted for
one day from the administrative records of the University. Four
different surgical methods were included: Gamma nailing and
Dinamic Hip Screw (DHS) providing early weight bearing; Ender
nailing and ﬁx angled plate (FAP) osteosynthesis providing
gradual partial weigh bearing. The average Hungarian Forint
(HUF) vale of one DRG cost-weigh was 100,000HUF. The
exchanga rate: 1USD = 230HUF. RESULTS: The average DRG
cost-weights: 2.87 for DHS, Ender nailing and FAP osteosyn-
thesis, and 4.47 for Gamma nailing. The average accommoda-
tion cost was 13,276HUF/patient/day. The average cost of
wages: 19,985HUF/patient/day. Drug cost: 404HUF/day.
Implants: FAP: 21,300HUF; Ender nail: 3780HUF; DHS:
33,400HUF; Gamma nail: 55,400HUF. The number of average
length of stay was: Gamma nailing and DHS: 8 days, Ender
nailing 10 days, FAP osteosynthesis 13 days. Comparing the
DRG reimbursement with the calculated hospital cost we
received the further balance: Gamma nailing: +122,280HUF;
DHS: -15,720HUF; Ender nailing: -45,610HUF; FAP osteosyn-
thesis -171,685HUF. CONCLUSIONS: We can conclude that
DRG reimbursement exceed the real hospital costs in Gamma
nailing. The hospital costs of DHS, Ender nailing and FAP
osteosynthesis are higher than the DRG reimbursement therefore
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